Marie Sébert

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

Cécile Bally, Lionel Adès, Aline Renneville et al. · Leukemia Research · 2014 · 159 citations

Medicine, Molecular Genetics, Oncology +17

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

Lionel Adès, Fabien Le Bras, Marie Sébert et al. · Haematologica · 2011 · 44 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience

Fabien Le Bras, Marie Sébert, Charikleia Kelaïdi et al. · Leukemia Research · 2011 · 39 citations

Medicine, Hematology, Oncology +12

USAID Associated with Myeloid Neoplasm and VEXAS Syndrome: Two Differential Diagnoses of Suspected Adult Onset Still’s Disease in Elderly Patients

M. Delplanque, Achille Aouba, Pierre Hirsch et al. · Journal of Clinical Medicine · 2021 · 32 citations · Full text

Medicine, Hematology, Internal Medicine +14

Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine

Marie Sébert, Rami S. Komrokji, Mikkael A. Sekeres et al. · Leukemia Research · 2017 · 16 citations · Full text

Medicine, Hematology, Oncology +16